Key points from article :
Diminished stem cell activity, ability to repair tissue, and immunosenescence cause frailty with ageing.
Longeveron's Mesenchymal Stem Cells have many mechanisms of action to address these issues.
Got approval of Japan's Pharmaceutical and Medical Devices Agency for phase 2 clinical trials.
Plans to determine if transplant of donor-derived MSC can improve healthspan in frail patients.
To be conducted at Juntendo University Hospital and National Center for Geriatrics and Gerontology.
